Drug intelligence / Profile preview

Picozyme ET

Development stage: Unknown
Lead developer: PICO Entech
Administration: Oral

Overview

Picozyme ET is a multi-ingredient health supplement developed by PICO Entech, specifically formulated to address essential tremor and support cognitive improvement. The product combines Aldehyde Dehydrogenase (ALDH) derived from dried yeast with phosphatidylserine and zinc. The mechanism of action centers on the enzymatic activity of ALDH, which plays a critical role in metabolizing aldehydes, although the precise molecular pathway by which this combination alleviates tremors is not fully defined. As of 2024, Picozyme ET is undergoing human application clinical trials at Korea University Anam Hospital to evaluate its efficacy in patients with tremors.

Brand names: Picozyme ET
Other names: 피코자임 이티

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)

Beyond the preview

Go deeper on Picozyme ET.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Picozyme ET.

Explore the full profile